免疫检查点抑制剂治疗老年晚期胃癌致大疱性类天疱疮1例  

Treatment of bullous pemphigoid caused by immune-checkpoint inhibitor in an elderly with advanced gastric cancer:1 case

作　　者：姚蓉蓉 梁晓华 YAO Rongrong;LIANG Xiaohua(Department of Oncology,Huashan Hospital,Fudan University,Shanghai 200040,China)

机构地区：[1]复旦大学附属华山医院肿瘤科,上海200040

出　　处：《上海医药》2025年第2期21-26,共6页Shanghai Medical & Pharmaceutical Journal

基　　金：复旦大学附属华山医院科学研究基金项目(2020QD010)。

摘　　要：皮肤不良反应为免疫检查点抑制剂常见的不良事件,而大疱性类天疱疮是少见类型,发病率<1%。本文介绍1例81岁营养不良的晚期胃癌患者,经免疫检查点抑制剂联合化疗治疗后,营养状态明显改善,肿瘤达到部分缓解。但治疗过程中出现难治性瘙痒、皮疹及大疱样皮损,经多学科会诊后最终诊断为免疫检查点抑制剂所致的大疱性类天疱疮。经多种方案治疗后在抗肿瘤治疗与皮肤不良反应之间达到平衡,皮损得到良好控制,停止免疫检查点抑制剂治疗1年后,肿瘤持续处于稳定中。Skin adverse reactions are the common adverse events of immune checkpoint inhibitors,while bullous pemphigoid is a rare type with an incidence of<1%.This article described an 81-year-old malnourished advanced gastric cancer patient who was treated with an immune checkpoint inhibitor combined with chemotherapy.The nutritional status was significantly improved,and the tumor achieved partial remission.However,refractory pruritus,rash and bullous lesions occurred during the course of treatment,and he was finally diagnosed with bullous pemphigoid caused by immune checkpoint inhibitors after multidisciplinary consultation.The balance between antitumor therapy and skin adverse reactions was achieved after treatment with multiple regimens.The skin lesions were well controlled,and the tumor continued to be stable after stopping immune checkpoint inhibitor therapy for one year.

关 键 词：老年 晚期胃癌 免疫检查点抑制剂 大疱性类天疱疮 

分 类 号：R730.51[医药卫生—肿瘤] R735.2[医药卫生—临床医学]